Janssen announced today that PONVORY has been granted reimbursement

Janssen announced that PONVORY was granted reimbursement for treatment of RMS with active disease defined by clinical or imaging features

PONVORY ^TM (ponesimod), a Once Daily, Oral Therapy approved for reimbursement in Ireland for adults with Relapsing Forms of Multiple Sclerosis with Active Disease Defined by Clinical or Imaging Features⁴

Janssen, the Pharmaceutical Companies of Johnson & Johnson, announced today that PONVORY ^TM (ponesimod) has been granted reimbursement in Ireland for the treatment of adults with relapsing multiple sclerosis (RMS) with active disease defined by clinical or imaging features.⁴